A systematic review and network meta-analysis of single nucleotide polymorphisms associated with oral submucous fibrosis risk.

Medicine (Baltimore)Sep 4, 2026
Clinical ResearchMedical GeneticsOncology (Medical)

Chunxia Huang, Juan Liu, Bin Zeng et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and network meta-analysis evaluated the association between single nucleotide polymorphisms (SNPs) and the risk of oral submucous fibrosis (OSF) in a population of 2545 cases and 3772 controls. The study identified several SNPs, notably CYP1A1 rs1048943:A>G, as significantly associated with increased OSF risk, with the dominant model of this SNP being the most strongly linked.

Key findings

  • CYP1A1 rs1048943:A>G was the most strongly associated SNP with OSF risk.
  • The dominant model of CYP1A1 rs1048943:A>G ranked first in association strength.
  • GSTT1 null genotype and GSTM1 null genotype were linked to increased OSF risk.
  • MMP2 rs243865:C>T and MMP3 rs3025058:5A>6A were associated with decreased OSF risk.

Why it matters

Understanding the genetic factors associated with OSF can help identify individuals at higher risk for this precancerous condition, potentially guiding early intervention and monitoring strategies in clinical practice.

Source

PubMed · PMID 42700036

Published in Medicine (Baltimore). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Medical Genetics

Clinical ResearchOncology (Medical)

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

This phase 3 randomized clinical trial evaluated the efficacy and safety of osimertinib combined with chemotherapy versus osimertinib alone in 294 patients with advanced non-small cell lung cancer (NSCLC) harboring…

JAMASep 8, 2026Open accessRead summary
Clinical ResearchHematology

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

This phase 2 randomized trial compared azacitidine plus venetoclax to induction chemotherapy in 172 previously untreated adults with acute myeloid leukemia (AML) eligible for induction.

N Engl J MedSep 3, 2026Read summary
Clinical ResearchPsychiatry

The efficacy of modified psychodynamic psychotherapy for patients with schizophrenia-spectrum disorders in Germany: a prospective, single-centre, assessor-blinded, parallel-group, randomised controlled trial.

This randomized controlled trial evaluated the efficacy of Modified Psychodynamic Psychotherapy for Schizophrenia (MPP-S) combined with treatment as usual (TAU) in 130 outpatients with schizophrenia-spectrum disorders…

Lancet PsychiatrySep 10, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.